With $70 million and a phase 2…
With $70 million and a phase 2 ready asset in [...]
“We need to pick a lane here as…
“We need to pick a lane here as a country. [...]
GSK and Spero Therapeutics have…
GSK and Spero Therapeutics have shared phase 3 results on [...]
After rejecting Replimune’s…
After rejecting Replimune’s melanoma drug RP1 this summer, the FDA [...]
The U.S. private equity market is…
The U.S. private equity market is showing signs of recovery, [...]
As scientific disinformation…
As scientific disinformation skyrockets, the Biotechnology Innovation Organization (BIO)—the world’s [...]
The company believes the data for…
The company believes the data for zanzalintinib validate its hopes [...]
Europe’s leading cancer…
Europe’s leading cancer conference may be swimming in ADC data, [...]
Tubulis’ next-generation ADC has…
Tubulis’ next-generation ADC has been tied to an overall response [...]
GSK may be happy with the latest…
GSK may be happy with the latest readouts from two [...]